Why 3Win s CCELL Vape Technology Dominates the Cannabis World With 9 out of 10 Brands and Over 77% of Vape Hardware Marketshare in California
PHOENIX - March 8, 2021 - ( Newswire.com )
In today’s booming cannabis industry, consumers have various methods of consuming cannabis products: smoking flower, edibles, tinctures, topicals, etc. But more and more commonly, “vaping” oil with the use of a cartridge and a battery, is now the most popular trend in the cannabis space from coast to coast.
In the early days of medical and recreational cannabis, the level of vape cartridge failure was notably high, and customer satisfaction was below average. The industry needed a leader, and then, in 2016, the CCELL product line took over the cannabis industry. Due to rigorous testing, CCELL built the most reliable cartridge on the market, with an almost 0% failure rate, then showed the ability to scale mass production to serve the largest customers on the market. The industry
Press release content from Business Wire. The AP news staff was not involved in its creation.
National Grid Transforms its Business with Appirio and Salesforce
March 8, 2021 GMT
INDIANAPOLIS (BUSINESS WIRE) Mar 8, 2021
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that Appirio, a Wipro company, is helping National Grid transform its business with an omnichannel customer experience by unifying its engagement with 68 million customers across two continents.
This global hybrid integration platform was recognized both for its positive business impact and for being among the first implementations of Runtime fabric for MuleSoft in the U.S. For this innovative work, Appirio has also been named the recipient of the Salesforce Partner Innovation Award for MuleSoft.
Press release content from Accesswire. The AP news staff was not involved in its creation.
Increasing Sales in Fabric Care Sector Drives Wrinkle Release Spray Market: Future Market Insights Report
March 8, 2021 GMT
Increasing consumer spending on fabric care is creating attractive opportunities, particularly in developing economies such as India, China, Brazil, the UAE, Russia, and Australia.
DUBAI, UAE / ACCESSWIRE / March 8, 2021 / Future Market Insights: FMI states in its recent study that the wrinkle release spray market will record an impressive CAGR of r% in the forecasted period 2020-2030. Demand for wrinkle release spray is anticipated to continue surging because The laundry sector is experiencing strong year-on-year growth.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Gilat Announces Filing of 2020 Annual Report
Gilat Satellite Networks Ltd.March 8, 2021 GMT
PETAH TIKVA, Israel, March 08, 2021 (GLOBE NEWSWIRE) Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announces that it has filed its Annual Report on Form 20-F containing audited consolidated financial statements for the year ended December 31, 2020 with the U.S. Securities and Exchange Commission.
The annual report will be available on the Gilat website ( www.gilat.com ). Shareholders may receive a hard copy of the annual report free of charge upon request.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline
March 8, 2021 GMT
ALAMEDA, Calif. & SHANGHAI (BUSINESS WIRE) Mar 8, 2021
Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics (“WuXi Bio”) (2269.HK) today announced the companies have entered into an exclusive license agreement to support the continued expansion of Exelixis’ oncology biologics pipeline. The agreement is the latest in a series of biologics-focused transactions for Exelixis as the company builds out its pipeline behind CABOMETYX ® (cabozantinib), its flagship product and global oncology franchise, which received its fourth approval from the U.S. Food and Drug Administration in January.